Novartis AG annual ebitda
2021
2022
2023
2024
2025
Novartis AG EBITDA Growth & History (NVS)
Novartis AG's calculated EBITDA was $18.59B for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.59B | $3.17B | +20.52% |
| 2024 | 2024-12-31 | $15.43B | −$2.83B | −15.48% |
| 2023 | 2023-12-31 | $18.25B | $9.15B | +100.41% |
| 2022 | 2022-12-31 | $9.11B | −$2.15B | −19.13% |
| 2021 | 2021-12-31 | $11.26B | — | — |
Novartis AG quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.13B | $55.0M | +0.91% |
| Q1 2026 | 2026-03-31 | $5.41B | — | — |
| Q4 2025 | 2025-12-31 | $5.07B | — | — |
| Q3 2025 | 2025-09-30 | $5.84B | — | — |
| Q2 2025 | 2025-06-30 | $6.08B | — | — |
Novartis AG ebitda trends
Between the periods ended 2021-12-31 and 2025-12-31, Novartis AG's ebitda increased from $11.26B to $18.59B, a change of $7.33B. The latest reported quarter, Q2 2026, shows $6.13B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...